$阿玛琳(AMRN)$ • Matinas BioPharma (NYSEMKT:MTNB) is now pre-screening patients for its Phase 2 ENHANCE-IT study that will directly compare MAT9001 against Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in patients with elevated triglycerides (150 - 499 mg/dL). Enrollment should start in Q1 2020 with topline results expected in H2 2020.
• The company says MAT9001, a next-generation omega-3 fatty acid compound, is more effective than Vascepa in lowering high triglycerides.